Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi
Oruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug saw their skin plaques ...
April 27, 2026 10:19 AM EDT R&D Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi Max Gelman Senior Editor Oruka Therapeutics’ Phase 2 psoriasis data could mean there’s a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that